Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 17, 2025 14:46 ET | Source: FastPassCorp A/S

FN1-2025 Kapitalforhøjelse - Udnyttelse af warrants

NASDAQ FIRST NORTH GROWTH MARKET MEDDELELSE NR. 1/2025 København, den 17. februar 2025 FN1/2025 Kapitalforhøjelse – Udnyttelse af warrants Bestyrelsen i FastPass har i dag besluttet at udnytte...
February 11, 2025 11:24 ET | Source: Arctic Wolf Networks, Inc

Arctic Wolf Named Official Cybersecurity Partner of BWT Alpine Formula One Team

EDEN PRAIRIE, Minn., Feb. 11, 2025 (GLOBE NEWSWIRE) -- BWT Alpine Formula One Team announces a partnership with Arctic Wolf, a global leader in Security Operations, Arctic Wolf becomes the Official...
February 11, 2025 07:30 ET | Source: Revival Gold Inc.

Revival Gold Advances Mercur for Potential Re-Development

TORONTO, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Revival Gold Inc. (TSXV: RVG, OTCQX: RVLGF) (“Revival Gold” or the “Company”) is pleased to provide an update on progress with the Company’s Mercur gold...
February 10, 2025 07:00 ET | Source: RespireRX Pharmaceuticals Inc.

RespireRx Pharmaceuticals Inc. CFO and CEO Issue Letter to Stockholders, Stakeholders, Strategic and Potential Strategic Partners and Other Interested Parties

Glen Rock, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments...
February 07, 2025 07:54 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Trading in Novo Nordisk shares by board members, executives and associated persons Bagsværd, Denmark, 7 February 2025 — This company announcement discloses the data of the transaction(s) made in Novo...
February 07, 2025 02:45 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S: Once-weekly Mim8 is well-tolerated and efficacious in children living with haemophilia A with and without inhibitors

Phase 3 FRONTIER3 interim analysis data presented at EAHAD 2025 showed that 74.3% of children on once-weekly Mim8 prophylaxis experienced zero treated bleeds Bagsværd, Denmark, 7 February 2025 –...
February 06, 2025 04:12 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Bagsværd, Denmark, 6 February 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated...
February 05, 2025 07:36 ET | Source: Novo Nordisk A/S

Novo Nordisk files annual report with the SEC

Bagsværd, Denmark, 5 February 2025 – Novo Nordisk A/S has filed its Annual Report 2024 on Form 20-F for the financial year 2024 with the US Securities and Exchange Commission (SEC), incorporating by...
February 05, 2025 01:30 ET | Source: Novo Nordisk A/S

Novo Nordisk's sales increased by 25% in Danish kroner and by 26% at constant exchange rates to DKK 290.4 billion in 2024

Bagsværd, 5 February 2025 - Financial report for the period 1 January 2024 to 31 December 2024 ...
February 04, 2025 07:57 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 4 February 2025 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and...